When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
LLY - Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade)
Eli Lilly and Company
2024-02-08 02:25:34 ET
Summary
Eli Lilly's tirzepatide shows potential in treating MASH, challenging Madrigal Pharmaceuticals' resmetirom.
Despite Madrigal's solid financials, Eli Lilly's advancements hint at market recalibration, adversely affecting Madrigal's valuation and future revenues.
MDGL maintains a strong financial position with a healthy cash reserve, reducing immediate capital needs despite operational cash consumption.
Recommend selling Madrigal's stock due to tirzepatide's competitive threat, despite its financial health and the speculative success of resmetirom.